The promise of bringing expensive medicines within reach
In keeping with our mission, generic medicines form the largest part of the Dr. Reddy’s product offering. Our strength in the generics business is a direct result of our research expertise and development capabilities in this field. What makes our Generics R&D operation distinctive is a unique combination of the depth and breath of capabilities, coupled with world-class infrastructure, sustainable partnerships and a robust product portfolio.
Our R&D philosophy for Generics has evolved along multiple dimensions – from simple, oral solid-based products to complex OSDs, injectable and dermatological products; from simple chemistry to semi-synthetic APIs, Chirals, Prostaglandins, Peptides and nano-particle based products; from established processes to advanced particle engineering solutions and complex scale-ups.
Our research organization has solved a number of complex challenges across oral solid dosage forms as well as injectable medicines – whether it is formulation complexity, API complexity, IP complexity or other challenges like bio-equivalence and process engineering.
欧美XaV 亞洲Xa VIn line with changing global needs, we have begun to shift our product mix, with 50% of the value of our US filings expected to come from non-OSDs over the next five years. To enable the shift, we’re building strong capabilities in complex clinical trials, complex scale-up or tech transfer, regulatory framework and advanced devices. Honing our capabilities in drug-device combinations is expected to have a continued focus in the future, along with building capabilities in the injectable and inhalation space.